Eli Lilly and Co.

Related Content

News | Cardiovascular Business

Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases

July 14, 2023 — Eli Lilly and Company and Versanis Bio today announced a definitive agreement for Lilly to acquire ...

July 14, 2023

Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse outcomes compared to men.

News | Womens Cardiovascular Health

Tackling Health Disparities and Inequities for Women with Heart Failure

April 21, 2022 – Despite a similar prevalence of the chronic condition, women diagnosed with heart failure have worse ...

April 21, 2022

$FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction. he U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for empagliflozin (Jardiance) as an investigational treatment for adults with heart failure with preserved ejection fraction (HFpEF).$

News | Pharmaceuticals

FDA Grants Empagliflozin Breakthrough Therapy Status for Heart Failure With Preserved Ejection Fraction

October 7, 2021 – The U.S. Food and Drug Administration (FDA) recently granted the breakthrough therapy designation for ...

October 07, 2021

News | Heart Failure

EMPRISE Study Shows Empagliflozin Reduces Heart Failure Hospitalization

November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) ...

November 07, 2018

heart stent, OAP therapy, ACS, patients, PCNA, SCAI, medication, prescribed

Feature

Half of Heart Stent Patients Don't Take Oral Antiplatelet Medication As Prescribed

May 6, 2015 — People with acute coronary syndrome (ACS) who undergo an angioplasty procedure and receive a heart stent ...

May 06, 2015

News

Studies Show Effect of Prasugrel vs. Clopidogrel on Readmissions, Initial Hospitalization Costs in ACS-PCI Patients

December 6, 2012 — Daiichi Sankyo Inc. and Eli Lilly and Co. announced results of two retrospective, observational ...

December 06, 2012

ADAPT-DES study TCT, 2012, Plavix, stent

Feature

Low Clopidogrel Responsiveness Predicts Stent Thrombosis, Heart Attack

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are ...

November 02, 2012

News

Tailored Therapy Using Clopidogrel is Superior to Prasugrel in Reducing High Platelet Reactivity

October 23, 2012 — A study found that a tailored therapy approach that adjusts the loading dose of clopidogrel according ...

October 23, 2012

News

TRILOGY ACS Shows Prasugrel Not Superior to Clopidogrel in Medically Managed Non-STEMI Patients Without Revascularization

September 6, 2012 — Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III ...

September 06, 2012

Ticagrelor, Brillinta, is the newest antiplatelet agent on the market. Ticagrelor is a reversible nonthienopyridine P2Y12 receptor antagonist that prevents signal transduction and platelet activation.

Feature | Antiplatelet and Anticoagulation Therapies| Nicole Fornell, Pharm D

New Data and Recent Advances in Antiplatelet Agents

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus ...

August 28, 2012